Recombinant vectors as influenza vaccines.
The antiquated system used to manufacture the currently licensed inactivated influenza virus vaccines would not be adequate during an influenza virus pandemic. There is currently a search for vaccines that can be developed faster and provide superior, long-lasting immunity to influenza virus as well as other highly pathogenic viruses and bacteria. Recombinant vectors provide a safe and effective method to elicit a strong immune response to a foreign protein or epitope. This review explores the advantages and limitations of several different vectors that are currently being tested, and highlights some of the newer viruses being used as recombinant vectors.
Kopecky-Bromberg
Sarah A
SA
Department of Microbiology, Mount Sinai School of Medicine, New York, NY 10029-6574, USA.
Palese
Peter
P
D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D005822:Genetic Vectors / Q000235:genetics*; D006801:Humans; D007252:Influenza Vaccines / Q000276:immunology*; D009522:Newcastle disease virus / Q000235:genetics; D009975:Orthomyxoviridae / Q000235:genetics; D011212:Poxviridae / Q000235:genetics; D014614:Vaccines, Synthetic / Q000276:immunology*; D018116:Vesiculovirus / Q000235:genetics
D007252:Influenza Vaccines; D014614:Vaccines, Synthetic